SCHEMBL2965273

SCHEMBL2965273

c1ccc(C2CCN(C3CC3)CC2)cc1

nearest known ligand 0.81

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SLC18A3 Q16572 8/20 0.81
GRIN2B Q13224 3/20 0.76
CYP2D6 P10635 3/20 0.76
CYP2C19 P33261 1/20 0.76
SMN1; SMN2 Q16637 3/20 0.68
HPGD P15428 1/20 0.68
KMT2A Q03164 1/20 0.68
TSHR P16473 2/20 0.58
CYP1A2 P05177 1/20 0.58
CYP2C9 P11712 1/20 0.58
SIGMAR1 Q99720 1/20 0.58
ALDH1A1 P00352 1/20 0.56
APEX1 P27695 1/20 0.56
BLM P54132 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cyanide SCHEMBL27976792 0.94 SLC18A3 (0.73) SLC18A3GRIN2BCYP2D6CYP2C19SMN1; SMN2
SCHEMBL30563652 0.92 SLC18A3 (0.96) SLC18A3GRIN2BCYP2D6CYP2C19SMN1; SMN2
SCHEMBL14004945 0.91 SLC18A3 (0.69) SLC18A3GRIN2BCYP2D6CYP2C19SMN1; SMN2
SCHEMBL13999220 0.91 SLC18A3 (0.69) SLC18A3GRIN2BCYP2D6CYP2C19SMN1; SMN2
SCHEMBL14004946 0.91 SLC18A3 (0.69) SLC18A3GRIN2BCYP2D6CYP2C19SMN1; SMN2
SCHEMBL7888827 0.90 SLC18A3 (1.00) SLC18A3GRIN2BCYP2D6CYP2C19SMN1; SMN2
SCHEMBL11121512 0.90 SLC18A3 (1.00) SLC18A3GRIN2BCYP2D6CYP2C19SMN1; SMN2
Hydrochloric Acid SCHEMBL7879553 0.88 SLC18A3 (0.96) SLC18A3GRIN2BCYP2D6CYP2C19SMN1; SMN2
SCHEMBL15184744 0.88 CYP2D6 (0.83) SLC18A3GRIN2BCYP2D6CYP2C19SMN1; SMN2
SCHEMBL13498019 0.87 CYP2D6 (1.00) SLC18A3GRIN2BCYP2D6CYP2C19SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110072860-B Compounds useful as immunomodulators 百时美施贵宝公司 2022-09-02 CN disclosed
US-10301267-B2 Compounds ASTRAZENECA AB (SE) 2019-05-28 US disclosed
US-20170260143-A1 NOVEL COMPOUNDS ASTRAZENECA AB (SE) 2017-09-14 US disclosed
US-9688640-B2 Methods of treating cancer with a pyrazole derivative ASTRAZENECA AB (SE) 2017-06-27 US disclosed
EP-2511267-A1 3-((N-ACYLATED AMINOACYL)AMINO)PYRAZOLES AS INHIBITORS OF BETA-AMYLOID PEPTIDE PRODUCTION USEFUL FOR THE TREATMENT OF ALZHEIMER'S DISEASE Elan Pharmaceuticals Inc. (US) 2012-10-17 EP disclosed
EP-1633350-B1 ACYLATED AMINO ACID AMIDYL PYRAZOLES AND RELATED COMPOUNDS ELAN PHARM INC (US) 2012-10-03 EP disclosed
US-20100280066-A1 ACYLATED AMINO ACID AMIDYL PYRAZOLES AND RELATED COMPOUNDS TUNG JAY S 2010-11-04 US disclosed
US-7759382-B2 such as N-{5-[1-(4-chloro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-2-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetylamino]-propionamide, used for inhibiting beta-amyloid peptide release and/or biosynthesis, inhibiting gamma-secretase activity, prevention and treatment of Alzheimer's disease ELAN PHARMACEUTICALS, INC. (US) 2010-07-20 US disclosed
EP-1633350-A4 ACYLATED AMINO ACID AMIDYL PYRAZOLES AND RELATED COMPOUNDS ELAN PHARM INC (US) 2008-11-26 EP disclosed
US-20070197624-A1 Acylated amino acid amidyl pyrazoles and related compounds ELAN PHARMACEUTICALS, INC. (US) 2007-08-23 US disclosed
EP-1633350-A2 ACYLATED AMINO ACID AMIDYL PYRAZOLES AND RELATED COMPOUNDS Elan Pharmaceuticals, Inc. (US) 2006-03-15 EP disclosed
WO-2005009344-A2 ACYLATED AMINO ACID AMIDYL PYRAZOLES AND RELATED COMPOUNDS ELAN PHARMACEUTICALS, INC. (US) 2005-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10301267-B2 Compounds SLC10A1, CYP11B1, ABCB11 SLC18A3 3899/4885GRIN2B 4094/4885CYP2D6 79/4885
US-20100280066-A1 ACYLATED AMINO ACID AMIDYL PYRAZOLES AND RELATED COMPOUNDS APP, BACE1, APH1A SLC18A3 414/4885GRIN2B 461/4885CYP2D6 2978/4885
US-20070197624-A1 Acylated amino acid amidyl pyrazoles and related compounds APP, BACE1, APH1A SLC18A3 414/4885GRIN2B 461/4885CYP2D6 2978/4885
US-20170260143-A1 NOVEL COMPOUNDS SLC10A1, ABCB11, CYP11B1 SLC18A3 3829/4885GRIN2B 3769/4885CYP2D6 595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.